Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Public ClinicalTrials.gov record NCT02402660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Study identification
- NCT ID
- NCT02402660
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 8 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2015 (Actual)
- Primary completion
- Jun 30, 2028 (Estimated)
- Completion
- Nov 30, 2028 (Estimated)
- Last update posted
- Sep 21, 2026
2015 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkeus Site | Phoenix | Arizona | 85020 | — |
| Alkeus Site | Los Angeles | California | 90095 | — |
| Alkeus Site | Aurora | Colorado | 80045 | — |
| Alkeus Site | Gainesville | Florida | 32601 | — |
| Alkeus Site | Miami | Florida | 33136 | — |
| Alkeus Site | Indianapolis | Indiana | 46202 | — |
| Alkeus Site | Baltimore | Maryland | 21287 | — |
| Alkeus Site | Grand Rapids | Michigan | 49546 | — |
| Alkeus Site | New York | New York | 10032 | — |
| Alkeus Site | Westbury | New York | 11590 | — |
| Alkeus Site | Houston | Texas | 77025 | — |
| Alkeus Site | Salt Lake City | Utah | 84132 | — |
| Alkeus Site | Silverdale | Washington | 98383 | — |
| Alkeus Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02402660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02402660 live on ClinicalTrials.gov.